Tom Conrad: Good afternoon, everyone, and thank you for joining us. Coming into fiscal 2026, my focus was straightforward. Build on the stability we reestablished in 2025 and start bending the ...
DelveInsight's Insulin Resistance Market Insights report includes a comprehensive understanding of current treatment practices, insulin resistance emerging drugs, market share of individual therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results